News Releases
Fibrocell Science, Inc. Announces Recognition for LAVIV™ (azficel-T) at The 2012 Cell & Gene Therapy Forum, Washington, D.C.
LAVIV™ named the #3 top story of 2011 in cell & gene therapy and regenerative medicine— EXTON, Pa., January 30, 2012 – Fibrocell Science, Inc. (OTCBB: FCSC), a biotechnology company focused on the development of autologous (personalized) cell therapies for aesthetic, medical and scientific applications, announces that the June 2011 FDA approval of LAVIV™ (azficel-T)Read more
Fibrocell Science, Inc. to Present at the 5th Annual OneMedForum San Francisco 2012
EXTON, Pa., January 4, 2012 – Fibrocell Science, Inc. (OTCBB: FCSC), a biotechnology company focused on the development of autologous (personalized) cell therapies for aesthetic, medical and scientific applications, announced today that David Pernock, the Company’s Chairman and CEO, will be presenting at the 5th Annual OneMedForum San Francisco 2012 to be held on JanuaryRead more
Fibrocell Science, Inc. to Present at the Oppenheimer 22nd Annual Healthcare Conference
EXTON, Pa., Dec 01, 2011 – Fibrocell Science, Inc. (OTCBB:FCSC.OB), a biotechnology company focused on the development of autologous (personalized) cell therapies for aesthetic, medical and scientific applications, announced today that David Pernock, the Company’s Chairman and CEO, will be presenting at the Oppenheimer 22nd Annual Healthcare Conference to be held on December 13-14, 2011Read more
Fibrocell Science, Inc. to Present at the Canaccord Genuity 6th Annual Cardiovascular, Aesthetics and Metabolic Disorders Conference
EXTON, Pa., November 23, 2011 – Fibrocell Science, Inc. (OTCBB:FCSC.OB), an biotechnology company focused on the development of autologous (personalized) cell therapies for aesthetic, medical and scientific applications, announced today that David Pernock, the Company’s Chairman and CEO, will be presenting at the Canaccord Genuity 6th Annual Cardiovascular, Aesthetics and Metabolic Disorders Conference to beRead more
Fibrocell Science, Inc. to Host Investor Conference Call to Discuss Third Quarter 2011 Business Update
EXTON, Pa., November 08, 2011 – Fibrocell Science, Inc. (OTCBB:FCSC.OB), an autologous cellular therapeutic company focused on the development of innovative products for aesthetic, medical and scientific applications, announced today that David Pernock, the Company’s Chairman and CEO, will host an investor conference call to discuss Fibrocell’s business update for the third quarter ended SeptemberRead more
Follow Us
